Factor Description should be no more than 3 sentences. Clinical Trial Results: Positive clinical trial data for FibroGen's roxadustat or other pipeline drugs often leads to increased investor confidence and higher stock prices. Conversely, negative or inconclusive trial results can cause a significant drop in price. Regulatory Approvals: Regulatory decisions by agencies like the FDA regarding FibroGen's drugs are crucial. Approvals typically boost the stock price, while rejections or delays can negatively impact it. Market Sentiment: Overall investor sentiment towards the biotechnology sector and FibroGen specifically influences the stock price. Positive market trends can lift FBRX, while negative trends can drag it down, regardless of company-specific news. Competition: The competitive landscape in the anemia and other therapeutic areas FibroGen targets affects the price. The emergence of new or improved therapies from competitors can pressure FBRX. Financial Performance: FibroGen's revenue, profitability, and cash flow influence investor perception. Strong financial results generally support a higher stock price, while weak financials can lead to declines.